InvestorsHub Logo
Followers 33
Posts 2859
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Wednesday, 04/27/2022 7:14:47 PM

Wednesday, April 27, 2022 7:14:47 PM

Post# of 932
By Q4 (GEN-011)

20-24 patients dosed.

Day 57 scans from 14-18 patients.

Up to 10 patients on schedule B3 (TIL-like).

Day 113 scans from 9-11 patients.

Up to 8 patients on schedule B3 (TIL-like).

Tumour mix: NSCLC, SCCHN, UC, and melanoma likely to predominate.

Biomarker data: ctDNA, tumour infiltration, TCR sequencing and proliferation and persistence.